GlobeNewswire – Page 22

LyondellBasell reports third quarter 2026 earnings

Posted on October 30, 2026 by Ravi Shankar

Net income: $758 million, $828 million excluding identified items¹
Diluted earnings per share: $2.32 per share, $2.54 per share excluding identified items
EBITDA: $1.4 billion, $1.5 billion excluding identified items
Continued strong EBITDA margin reflecting the resilience of our global, cost-advantaged portfolio, ongoing execution of our Value Enhancement Program and diversified end market exposure
Demonstrated operational excellence through improved asset reliability and completion of the Clinton turnaround on time and under budget
Increased cash by approximately $600 million during the quarter including planned €500 million debt repayment
Progressed our Cash Improvement Plan including reducing global structural fixed costs

HOUSTON and LONDON, Oct. 30, 2026 (GLOBE NEWSWIRE) — LyondellBasell Industries (NYSE: LYB) (the “company”) today announced results for the third quarter 2026. Comparisons with the prior quarter and third quarter 2025 are available in the following table:

Table 1 – Earnings Summary

*Millions of U.S. dollars (except share data)*	Three Months Ended							Nine Months Ended
*Millions of U.S. dollars (except share data)*	September 30, 2026		June 30, 2026		September 30, 2025			September 30, 2026		September 30, 2025
Sales and other operating revenues	$	8,499	$	9,177	$	7,727		$	24,873	$	23,062
Net income (loss)		758		559		(890	)		1,442		(598	)
Diluted earnings (loss) per share		2.32		1.71		(2.77	)		4.42		(1.89	)
Weighted average diluted share count		323		323		322			323		322
EBITDA¹		1,420		1,252		(480	)		3,240		781

Excluding Identified Items¹

Net income excluding identified items	$	828		$	1,401		$	330	$	2,392		$	642
Diluted earnings per share excluding identified items		2.54			4.30			1.01		7.34			1.96
Loss on sale of business, pre-tax		—			734			6		734			6
Asset write-downs, pre-tax		—			74			1,202		89			1,234
Cash Improvement Plan costs, pre-tax		2			31			7		33			27
Site closure costs, pre-tax		77			30			—		111			117
European transaction costs, net of transition service agreement income, pre-tax		(9	)		(11	)		17		(10	)		27
(Income) loss from discontinued operations, pre-tax		22			17			83		57			(66	)
EBITDA excluding identified items		1,512			2,127			835		4,254			2,126

_{(1) See “Information Related to Financial Measures” for a discussion of the company’s use of non-GAAP financial measures and Tables 2-4 for reconciliations or calculations of these financial measures. “Identified items” include adjustments for lower of cost or market (“LCM”), gain/loss on sale of business, asset write-downs in excess of $10 million in aggregate for the period, Cash Improvement Plan costs, site closure costs, European transaction costs, net of transition service agreement income, and discontinued operations.}

“In an evolving macroeconomic environment, we delivered another quarter of strong earnings and robust cash conversion through disciplined execution underscored by the strength of our global, cost-advantaged portfolio,” said Peter Vanacker, LYB chief executive officer. “We are leveraging the flexibility and resilience of our leaner structure by optimizing feedstocks, directing products to the most attractive markets and aligning operating rates with demand. The strength of our oxyfuels business and materially higher Intermediates and Derivatives profitability highlight the benefits of our diversified portfolio. We continue to prioritize safety, reliability and cost discipline, to maximize margins, generate cash and deliver sustainable value for our shareholders.”

THIRD QUARTER 2026 RESULTS
The company reported net income for the third quarter 2026 of $758 million, or $2.32 per diluted share. During the quarter, the company recognized $70 million of identified items, net of tax. These items, which impacted third quarter earnings by $0.22 per diluted share, included closure costs for a European propylene oxide (PO) joint venture. Third quarter 2026 EBITDA was $1.4 billion, or $1.5 billion excluding identified items.

Market conditions remained dynamic throughout the third quarter, as ongoing geopolitical uncertainty led to diverging impacts in our key markets. Compared with the second quarter, profitability fell in the Olefins and Polyolefins (O&P) – Americas segment, driven by lower prices for polymers and olefin products. However, the industry’s integrated polyethylene margins ended the third quarter at approximately 50% above 2025 levels, supported by positive polyethylene price momentum in September. The company completed the planned turnaround at Clinton on time and under budget, reflecting the ongoing focus on operational excellence. In the O&P – Europe, Asia and International segment, polymer prices fell which pressured margins. Volumes in the third quarter were also lower sequentially, reflecting the sale of certain European assets in May 2026.

Intermediates and Derivatives (I&D) delivered materially higher quarterly profitability, largely driven by oxyfuels. Through the Value Enhancement Program, LYB increased utilization of the Channelview PO/TBA asset to approximately 110%. Bayport PO/TBA operated at full rates after a successful restart in June, leveraging strong customer demand and providing additional support to earnings. Global supply disruptions led to higher crack spreads, and favorable gasoline blend economics boosted octane values. These factors significantly expanded Europe and U.S. oxyfuel margins. Acetyls also benefited from improved reliability at La Porte.

LYB generated $1.7 billion in cash from operating activities during the third quarter, including a release of working capital. Capital allocation was balanced between capital expenditures of $303 million and $224 million of shareholder returns through dividends. The company also repaid its €500 million note maturity in September as planned. At the end of the quarter, LYB held $3.2 billion in cash and cash equivalents and $7.7 billion in available liquidity.

OUTLOOK
Conditions in the Middle East are likely to remain fluid and a potential return to pre-conflict conditions is likely to be non-linear and take longer than anticipated. Customer buying patterns have been impacted by inventory levels and price volatility, however polyethylene domestic and export demand is strong and polymer pricing improved through the end of the third quarter. Additionally, oxyfuels margins and demand remain strong. As markets continue to adjust, reliable supply and operational flexibility are expected to remain important differentiators. The company’s cost-advantaged assets and exposure to diverse end markets are well positioned to underpin future earnings and cash flow.

In the fourth quarter, we expect normal seasonal demand patterns along with ongoing supply uncertainty. The company has a planned maintenance project in a North American polypropylene asset. To align with global demand and the company’s planned maintenance, LYB expects fourth quarter operating rates of 85% for North American O&P assets, 60% for European O&P assets and 75% for I&D assets. The fourth quarter is expected to deliver a seasonal release of working capital.

LYB remains focused on commercial and operational agility in this dynamic market while continuing to execute the Cash Improvement Plan. The company’s capital allocation priorities remain unchanged: safely operate and maintain assets, strengthen the balance sheet through disciplined deleveraging, maintain an attractive dividend and invest selectively in opportunities that enhance long-term shareholder value.

CONFERENCE CALL
LYB will host a conference call Oct. 30 at 11 a.m. EDT. Participants on the call will include CEO Peter Vanacker, Executive Vice President (EVP) and Chief Financial Officer Agustin Izquierdo, EVP of Global O&P Kim Foley, EVP of I&D Aaron Ledet, EVP of Advanced Polymer Solutions Torkel Rhenman and Head of Investor Relations David Dennison. For event access, the toll-free dial-in number is 1-877-407-8029, international dial-in number is 201-689-8029 or click the CallMe link. The slides and webcast that accompany the call will be available at investors.lyondellbasell.com/earnings. A replay of the call will be available from 1 p.m. EDT Oct. 30 until Nov. 30, 2026. The replay toll-free dial-in numbers are 1-877-660-6853 and 201-612-7415. The access ID for each is 13746219.

ABOUT LYONDELLBASELL
We are LyondellBasell (NYSE: LYB), a global leader in the chemical industry. We develop, manufacture and market innovative products for applications ranging from transportation and infrastructure to food safety, clean water and quality healthcare.

We hold leading positions in polyolefins, oxyfuels, propylene oxide and acetyls. Our focus on safe and reliable operations, proprietary technologies and strong portfolio positions us for success. Through disciplined investments, we strengthen our core businesses, and build profitable circular and low-carbon solutions that create long-term value for our customers, investors and other stakeholders.

Our commitment to an inclusive global workplace enables employees to do their best work as they create solutions for everyday sustainable living. For more information, please visit https://lyondellbasell.com or follow @LyondellBasell on LinkedIn.

FORWARD-LOOKING STATEMENTS
The statements in this release relating to matters that are not historical facts are forward-looking statements. These forward-looking statements are based upon assumptions of management of LyondellBasell which are believed to be reasonable at the time made and are subject to significant risks and uncertainties. When used in this release, the words “estimate,” “believe,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “will,” “expect,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Actual results could differ materially based on factors including, but not limited to, market conditions, including the prolonged industry downturn, the business cyclicality of the chemical and polymers industries; the availability, cost and price volatility of raw materials and utilities, particularly the cost of oil, natural gas, and associated natural gas liquids; our ability to successfully implement initiatives identified pursuant to our Value Enhancement Program and generate anticipated earnings; competitive product and pricing pressures; labor conditions; our ability to attract and retain key personnel; operating interruptions (including leaks, explosions, fires, weather-related incidents, mechanical failure, unscheduled downtime, supplier disruptions, labor shortages, strikes, work stoppages or other labor difficulties, transportation interruptions, spills and releases and other environmental risks); the supply/demand balances for our and our joint ventures’ products; industry production capacities, operating rates, and the pace of global capacity rationalizations; the impacts and scope of the global supply disruption resulting from the conflict in Ukraine and the Middle East; our ability to manage costs; future financial and operating results; our ability to complete capital projects on time and on budget and successfully operate the asset; our ability to align our assets and grow and upgrade our core; our ability to reduce our fixed costs and increase cash flow; legal and environmental proceedings; tax rulings and related consequences or proceedings; the impacts of tariffs and trade disruptions; technological developments, and our ability to develop new products and process technologies; our ability to meet our sustainability goals, including the ability to operate safely, increase production of recycled and renewable-based polymers to meet our targets and forecasts, and reduce our emissions and achieve net zero emissions by the time set in our goals; our ability to procure energy from renewable sources; our ability to build a profitable Circular & Low Carbon Solutions business; our ability to improve the business performance of our Advanced Polymer Solutions segment and its ability to secure new customers; potential governmental regulatory actions; political unrest and terrorist acts; risks and uncertainties posed by international operations, including foreign currency fluctuations; our ability to maintain our investment-grade credit rating and execute our capital allocation strategy, including our ability to pay dividends; and our ability to comply with debt covenants and to repay our debt. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the “Risk Factors” section of our Form 10-K for the year ended December 31, 2025, which can be found at www.LyondellBasell.com on the Investors page and on the Securities and Exchange Commission’s website at www.sec.gov. There is no assurance that any of the actions, events or results of the forward-looking statements will occur, or if any of them do, what impact they will have on our results of operations or financial condition. Forward-looking statements speak only as of the date they were made and are based on the estimates and opinions of management of LyondellBasell at the time the statements are made. LyondellBasell does not assume any obligation to update forward-looking statements should circumstances or management’s estimates or opinions change, except as required by law.

INFORMATION RELATED TO FINANCIAL MEASURES
This release makes reference to certain non-GAAP financial measures as defined in Regulation G of the U.S. Securities Exchange Act of 1934, as amended.

We report our financial results in accordance with U.S. generally accepted accounting principles (“GAAP”), but believe that certain non-GAAP financial measures, such as EBITDA, and EBITDA, net income and diluted EPS exclusive of identified items provide useful supplemental information to investors regarding the underlying business trends and performance of the company’s ongoing operations and are useful for period-over-period comparisons of such operations. Non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to, the financial measures prepared in accordance with GAAP.

We calculate EBITDA as net income (loss) plus interest expense, net, provision for (benefit from) income taxes, and depreciation and amortization. EBITDA should not be considered an alternative to profit or operating profit for any period as an indicator of our performance, or as an alternative to operating cash flows as a measure of our liquidity. We also present EBITDA, net income and diluted EPS exclusive of identified items. Identified items include adjustments for lower of cost or market (“LCM”), gain/loss on sale of business, asset write-downs in excess of $10 million in aggregate for the period, Cash Improvement Plan costs, site closure costs, European transaction costs, net of transition service agreement income, and discontinued operations. Asset write-downs include impairments of goodwill and impairments of long-lived assets. Our inventories are stated at the lower of cost or market. Cost is determined using the last-in, first-out (“LIFO”) inventory valuation methodology, which means that the most recently incurred costs are charged to cost of sales and inventories are valued at the earliest acquisition costs. Fluctuation in the prices of crude oil, natural gas and correlated products from period to period may result in the recognition of charges to adjust the value of inventory to the lower of cost or market in periods of falling prices and the reversal of those charges in subsequent interim periods, within the same fiscal year as the charge, as market prices recover. A gain/loss on sale of a business is calculated as the consideration received from the sale less its carrying value. We evaluate property, plant and equipment and definite-lived intangible assets whenever impairment indicators are present. If it is determined that an asset or asset group’s undiscounted future cash flows will not be sufficient to recover the carrying amount, an impairment charge is recognized to write the asset down to its estimated fair value. Goodwill is tested for impairment annually in the fourth quarter or whenever events or changes in circumstances indicate that the fair value of a reporting unit with goodwill is below its carrying amount. If it is determined that the carrying value of the reporting unit including goodwill exceeds its fair value, an impairment charge is recognized. We assess our equity investments for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment may not be recoverable. If the decline in value is considered to be other-than-temporary, the investment is written down to its estimated fair value. In June 2025, we announced the divestiture of select olefins and polyolefins assets and the associated businesses in Europe, in May 2026 we completed the divestiture. In connection with the divestiture we recognized selling expenses, separation costs and employee-related charges (collectively referred to as “European transaction costs”), income from the transition service agreement and loss on sale of business. In April 2025, the company announced the Cash Improvement Plan, focused on strengthening financial performance, which resulted in employee-related charges across all segments. In March 2025, we announced the permanent closure of our Dutch PO joint venture asset, resulting in the recognition of shutdown-related charges in our Intermediates & Derivatives (“I&D”) segment. Additionally, we recognized shutdown and employee-related charges related to sites in our Advanced Polymer Solutions (“APS”) and Olefins & Polyolefins – Europe, Asia, International (“O&P-EAI”) segments. In February 2025, we ceased business operations at our Houston refinery. Accordingly, our refining business, previously disclosed as the Refining segment, is reported as a discontinued operation.

These non-GAAP financial measures as presented herein, may not be comparable to similarly titled measures reported by other companies due to differences in the way the measures are calculated. In addition, we include calculations for certain other financial measures to facilitate understanding. This release contains time sensitive information that is accurate only as of the time hereof. Information contained in this release is unaudited and subject to change.

LyondellBasell undertakes no obligation to update the information presented herein except to the extent required by law.

Additional operating and financial information may be found on our website at investors.lyondellbasell.com.

Source: LyondellBasell Industries

Investor Contact: David Dennison +1 713-309-4987
Media Contact: Barrie Lee +1 713-309-4791

Table 2 – Reconciliations of Net Income (Loss) to Net Income Excluding Identified Items and to EBITDA Including and Excluding Identified Items
	Three Months Ended									Nine Months Ended
Millions of U.S. dollars	September 30, 2026			June 30, 2026			September 30, 2025			September 30, 2026			September 30, 2025
Net income (loss)	$	758		$	559		$	(890	)	$	1,442		$	(598	)
Identified items
add: Loss on sale of business, pre-tax^(a)		—			734			6			734			6
add: Asset write-downs, pre-tax^(b)		—			74			1,202			89			1,234
add: Cash Improvement Plan costs, pre-tax^(c)		2			31			7			33			27
add: Site closure costs, pre-tax^(d)		77			30			—			111			117
add: European transaction costs, net of transition service agreement income, pre-tax^(e)		(9	)		(11	)		17			(10	)		27
less: (Income) loss from discontinued operations, pre-tax		22			17			83			57			(66	)
less: Benefit from income taxes related to identified items		(22	)		(33	)		(95	)		(64	)		(105	)
Net income excluding identified items	$	828		$	1,401		$	330		$	2,392		$	642

Net income (loss)	$	758		$	559		$	(890	)	$	1,442		$	(598	)
Provision for (benefit from) income taxes		183			232			(49	)		409			91
Depreciation and amortization		370			347			350			1,059			1,005
Interest expense, net		109			114			109			330			283
EBITDA		1,420			1,252			(480	)		3,240			781
Identified items
add: Loss on sale of business^(a)		—			734			6			734			6
add: Asset write-downs^(b)		—			74			1,202			89			1,234
add: Cash Improvement Plan costs^(c)		2			31			7			33			27
add: Site closure costs^(d)		77			30			—			111			117
add: European transaction costs, net of transition service agreement income^(e)		(9	)		(11	)		17			(10	)		27
less: EBITDA from discontinued operations		22			17			83			57			(66	)
EBITDA excluding identified items	$	1,512		$	2,127		$	835		$	4,254		$	2,126

_{(a) In May 2026, we disposed of select European O&P assets and the associated businesses, resulting in the recognition of a loss in our O&P-EAI segment. In September 2025, we sold our U.S. specialty powders business, resulting in the recognition of a loss in our APS segment.}
_{(b) Includes asset write-downs in excess of $10 million in aggregate for the period. For the nine months ended September 30, 2026, we recognized non-cash asset write-downs of $89 million, including a $74 million impairment charge recognized in the second quarter related to a plastic waste sorting facility in Houston, Texas, within our Olefins & Polyolefins – Americas segment and $15 million related to property, plant and equipment (“PP&E”) in the O&P-EAI segment. For the nine months ended September 30, 2025, we recognized non-cash asset write-downs of $1,234 million, which included non-cash goodwill impairment charges of $400 million in our O&P-EAI segment and $572 million in our APS segment, non-cash impairment charges of $111 million for intangible assets and $99 million for PP&E in our APS segment, and non-cash impairment charges of $43 million for PP&E related to the European assets classified as held for sale within our O&P-EAI segment.}
_{(c) In April 2025, the company announced the Cash Improvement Plan, focused on strengthening financial performance, which resulted in employee-related charges across all segments.}
_{(d) In March 2025, we announced the permanent closure of our Dutch PO joint venture asset, resulting in shutdown-related charges of $76 million and $117 million for the nine months ended September 30, 2026 and 2025, respectively, within our I&D segment. Additionally, for the nine months ended September 30, 2026, we recognized $31 million of employee-related charges related to the planned closure of our polypropylene asset in Brindisi, Italy, within our O&P-EAI segment.}
_{(e) In June 2025, we announced plans to sell select European O&P assets and the associated businesses, resulting in selling expenses, separation costs and employee-related charges in our O&P-EAI segment. Transition service agreement income was $10 million and $18 million, for the three and nine months ended September 30, 2026, respectively.}

Table 3 – Reconciliation of Diluted EPS to Diluted EPS Excluding Identified Items
	Three Months Ended									Nine Months Ended
	September 30, 2026			June 30, 2026			September 30, 2025			September 30, 2026			September 30, 2025
Diluted earnings (loss) per share	$	2.32		$	1.71		$	(2.77	)	$	4.42		$	(1.89	)
Identified items
add: Loss on sale of business		—			2.27			0.02			2.27			0.02
add: Asset write-downs^(a)		—			0.18			3.51			0.21			3.58
add: Cash Improvement Plan costs		0.01			0.07			0.01			0.08			0.06
add: Site closure costs		0.17			0.06			—			0.24			0.27
add: European transaction costs, net of transition service agreement income		(0.02	)		(0.03	)		0.05			(0.02	)		0.08
less: (Income) loss from discontinued operations		0.06			0.04			0.19			0.14			(0.16	)
Diluted earnings per share excluding identified items	$	2.54		$	4.30		$	1.01		$	7.34		$	1.96

_{(a) Includes asset write-downs in excess of $10 million in aggregate for the period.}

Table 4 – Calculation of Cash and Liquid Investments and Total Liquidity
Millions of U.S. dollars	September 30, 2026
Cash and cash equivalents	$	3,227
Restricted cash		8
Short-term investments		—
Cash and liquid investments		3,235
add:
Availability under Senior Revolving Credit Facility		3,750
Availability under U.S. Receivables Facility		700
Total liquidity	$	7,685

Posted in UncategorizedTagged GlobeNewswire

Willis Lease Finance Corporation Declares Fourth Quarter 2026 Dividend and Renewal and Increase of Share Repurchase Plan

Posted on October 30, 2026 by Ravi Shankar

COCONUT CREEK, Fla., Oct. 30, 2026 (GLOBE NEWSWIRE) — Willis Lease Finance Corporation (NASDAQ: WLFC) (“WLFC” or the “Company”), announced today the Company’s quarterly dividend of $0.15 per share of common stock outstanding. The dividend is expected to be paid on November 25, 2026, to stockholders of record at the close of business on November 16, 2026. This will be the Company’s 10^th consecutive quarterly dividend and reflects a 12.8% increase from our prior August distribution. In addition, the Company today announced that its Board of Directors has approved the renewal and increase of its share repurchase program under which the Company may repurchase its common stock for an aggregate purchase price of up to $200.0 million (the “Share Repurchase Program”) through December 31, 2031.

About Willis Lease Finance Corporation

Willis Lease Finance Corporation leases large and regional spare commercial aircraft engines and aircraft to airlines, aircraft engine manufacturers and maintenance, repair, and overhaul providers worldwide. These leasing activities are integrated with engine and aircraft trading, engine lease pools, and asset management services through Willis Mitsui & Co. Asset Management Limited, as well as various end-of-life solutions for engines and aviation materials provided through Willis Aeronautical Services, Inc. Through Willis Engine Repair Center®, Jet Centre by Willis, and Willis Aviation Services Limited, the Company’s service offerings include Part 145 engine maintenance, aircraft line and base maintenance, aircraft disassembly, parking and storage, airport FBO and ground and cargo handling services.

Except for historical information, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties. Do not unduly rely on forward-looking statements, which give only expectations about the future and are not guarantees. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them to reflect any change in the Company’s expectations or any change in events, conditions, or circumstances on which the forward-looking statement is based, except as required by law.

The Company’s actual results may differ materially from the results discussed in forward-looking statements. Factors that might cause such a difference include, but are not limited to: the effects on the airline industry and the global economy of events such as war, terrorist activity and the COVID-19 pandemic; changes in oil prices, rising inflation and other disruptions to world markets; trends in the airline industry and the Company’s ability to capitalize on those trends, including growth rates of markets and other economic factors; risks associated with owning and leasing jet engines and aircraft; the Company’s ability to successfully negotiate equipment purchases, sales and leases, to collect outstanding amounts due and to control costs and expenses; changes in interest rates and availability of capital, both to the Company and its customers; the Company’s ability to continue to meet changing customer demands; regulatory changes affecting airline operations, aircraft maintenance, accounting standards and taxes; the market value of engines and other assets in the Company’s portfolio; and risks detailed in the Company’s Annual Report on Form 10-K and other continuing and current reports filed with the Securities and Exchange Commission. It is advisable, however, to consult any further disclosures the Company makes on related subjects in such filings. These statements constitute the Company’s cautionary statements under the Private Securities Litigation Reform Act of 1995.

CONTACT:	Scott B. Flaherty
	Executive Vice President & Chief Financial Officer
	561.413.0112

Posted in UncategorizedTagged GlobeNewswire

Willis Lease Finance Corporation Declares Fourth Quarter 2026 Dividend and Renewal and Increase of Share Repurchase Plan

Posted on October 30, 2026 by Ravi Shankar

About Willis Lease Finance Corporation

CONTACT:	Scott B. Flaherty
	Executive Vice President & Chief Financial Officer
	561.413.0112

Posted in UncategorizedTagged GlobeNewswire

nVent Electric plc Third Quarter 2026 Financial Results Available on Company’s Website

Posted on October 30, 2026 by Ravi Shankar

LONDON, Oct. 30, 2026 (GLOBE NEWSWIRE) — nVent Electric plc (NYSE:NVT) (“nVent”), a global leader in electrical connection and protection solutions, reported third quarter 2026 financial results today through an earnings release posted on the company’s Investor Relations website at http://investors.nvent.com. The earnings release will be furnished with the Securities and Exchange Commission on a Form 8-K and is available here. The company will also hold a conference call with analysts and investors at 9:00 a.m. ET.

Conference Call and Webcast Details

The call can be accessed via webcast at http://investors.nvent.com or by dialing 1-833-630-1071 or 1-412-317-1832. Once available, a replay of the conference call will be accessible through November 13, 2026, by dialing 1-855-669-9658 or 1-412-317-0088, along with the access code 6922418.

About nVent
nVent is a leading global provider of electrical connection and protection solutions. We believe our inventive electrical solutions enable safer systems and ensure a more secure world. We design, manufacture, market, install and service high performance products and solutions that connect and protect some of the world’s most sensitive equipment, buildings and critical processes. We offer a comprehensive range of systems protection and electrical connections solutions across industry-leading brands that are recognized globally for quality, reliability and innovation. Our principal office is in London and our management office in the United States is in Minneapolis. Our robust portfolio of leading electrical product brands dates back more than 100 years and includes nVent CADDY, ERICO, HOFFMAN, ILSCO, SCHROFF and TRACHTE. Learn more at www.nvent.com.

nVent, CADDY, ERICO, HOFFMAN, ILSCO, SCHROFF and TRACHTE are trademarks owned or licensed by nVent Services GmbH or its affiliates.

Investor Contact
Tony Riter
Vice President, Investor Relations
nVent
763.204.7750
Tony.Riter@nVent.com

Media Contact
Kevin H. King
Vice President, Global Communications
nVent
763.291.0526
Kevin.King@nVent.com

Posted in UncategorizedTagged GlobeNewswire

nVent Electric plc Third Quarter 2026 Financial Results Available on Company’s Website

Posted on October 30, 2026 by Ravi Shankar

Conference Call and Webcast Details

nVent, CADDY, ERICO, HOFFMAN, ILSCO, SCHROFF and TRACHTE are trademarks owned or licensed by nVent Services GmbH or its affiliates.

Investor Contact
Tony Riter
Vice President, Investor Relations
nVent
763.204.7750
Tony.Riter@nVent.com

Media Contact
Kevin H. King
Vice President, Global Communications
nVent
763.291.0526
Kevin.King@nVent.com

Posted in UncategorizedTagged GlobeNewswire

NaaS Technology Inc.’s Parent Company Enters a Strategic Partnership with Tencent Cloud to Strengthen AI-Empowered Charging Services

Posted on October 30, 2026 by Ravi Shankar

BEIJING, Oct. 30, 2026 (GLOBE NEWSWIRE) — Newlinks Technology Limited (“Newlinks”), the parent company of NaaS Technology Inc. (Nasdaq: NAAS) (“NaaS” or the “Company”), announced that it signed a strategic cooperation agreement with Tencent Cloud at the 2026 Tencent Global Digital Ecosystem Summit held in Shenzhen on October 29, 2026. Under the agreement, the two parties will collaborate in cloud services, artificial intelligence (AI) and the Energy Internet of Things (Energy IoT), jointly exploring innovative applications of AI technology in the energy sector and advancing the evolution of energy digitalization toward intelligent operations.

Held under the theme “Collective Intelligence and the Data Flywheel: Unleashing Productivity Across All Scenarios,” the summit highlighted the practical path of AI agents evolving from individual productivity gains to enterprise-wide, full-scenario productivity. The collaboration with Tencent Cloud reflects the extension of AI capabilities into energy digitalization scenarios.

Newlinks was named among China’s Top 500 private enterprises. Focused on energy digitalization, Newlinks is committed to enhancing the stability and efficiency of global transportation energy networks. Over the decade since its founding, it has developed a “NewLink as a Service” business model that connects participants across the upstream and downstream of the energy industry, serving approximately hundreds of millions of vehicle owners and tens of thousands of enterprise customers as of the date of this press release. Its new energy business covers more than 200,000 charging stations while its refined oil products business connects approximately 26,000 gas stations, with a footprint spanning approximately 1,800 towns and cities across China. NaaS Technology Inc. (Nasdaq: NAAS), its subsidiary, is the first U.S.-listed EV charging service company in China.

Tencent Cloud is a cloud computing brand with strong capabilities in cloud computing, big data and AI. Under this collaboration, the two parties intend to leverage their respective strengths to cooperate in AI. Through Tencent Cloud’s data platform, as well as AI-driven tools including WorkBuddy and TokenHub, the two parties expect to deepen the application of AI across energy retail and energy management scenarios, with the aim of improving operational efficiency and user experience.

The Company believes that this collaboration represents a meaningful step by an energy digitalization enterprise and a cloud service provider toward accelerating the empowerment of AI in business development. Leveraging its extensive charging network coverage in the new energy vehicle charging sector and combining it with Tencent Cloud’s AI and cloud capabilities, NaaS aims to bring more convenient energy service experiences and higher operating efficiency to both users and charging stations, and will continue to contribute to the green transformation of China’s transportation energy sector.

About NaaS Technology Inc.

NaaS Technology Inc. is the first U.S.-listed EV charging service company in China. The Company is a subsidiary of Newlinks, a leading energy digitalization group in China, and is one of the leading providers of new energy asset operation services. The Company uses advanced technology to intelligently match charging supply with demand, offering EV users a seamless, efficient and smart charging experience, while empowering charging stations and operators to optimize operations, improve efficiency and enhance profitability.

Safe Harbor Statement

This press release contains statements of a forward-looking nature. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by terminology such as “will,” “expects,” “believes,” “anticipates,” “intends,” “estimates” and similar statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company and the industry. All information provided in this press release is as of the date hereof, and the Company undertakes no obligation to update any forward-looking statements to reflect subsequent events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: NaaS’ goals and strategies; its future business development, financial condition and results of operations; its ability to continuously develop new technologies, services and products and keep pace with changes in the industries in which it operates; the growth of China’s EV charging industry and NaaS’ future business development; the demand for and market acceptance of NaaS’ products and services; NaaS’ ability to protect and enforce its intellectual property rights; NaaS’ ability to attract and retain qualified executives and personnel; fluctuations in the RMB exchange rate and NaaS’ ability to obtain adequate financing; NaaS’ relationships with end users, customers, suppliers and other business partners; competition in the industry; relevant government policies and regulations; and fluctuations in general economic and business conditions in China and globally. Further information regarding these and other risks is included in NaaS’ filings with the SEC.

For investor and media inquiries, please contact:

Investor Relations
NaaS Technology Inc.
E-mail: ir@enaas.com

Media inquiries:
E-mail: pr@enaas.com

Posted in UncategorizedTagged GlobeNewswire

NaaS Technology Inc.’s Parent Company Enters a Strategic Partnership with Tencent Cloud to Strengthen AI-Empowered Charging Services

Posted on October 30, 2026 by Ravi Shankar

About NaaS Technology Inc.

Safe Harbor Statement

For investor and media inquiries, please contact:

Investor Relations
NaaS Technology Inc.
E-mail: ir@enaas.com

Media inquiries:
E-mail: pr@enaas.com

Posted in UncategorizedTagged GlobeNewswire

Regeneron Reports Third Quarter 2026 Financial and Operating Results

Posted on October 30, 2026 by Ravi Shankar

Third quarter 2026 revenues increased 36% to $5.1 billion versus third quarter 2025
Dupixent^® global net sales (recorded by Sanofi) increased 35% to $6.5 billion
EYLEA HD^®U.S. net sales increased 62% to $699 million
Libtayo^® global net sales increased 51% to $550 million
GAAP EPS increased 35% to $18.45; non-GAAP EPS^(a)increased 70% to $20.07
Expanded collaboration with Sanofi, adding multiple next-generation, long-acting immunology antibodies; $1.0 billion up-front to be recognized as collaboration revenue in fourth quarter 2026 with potential to receive up to an additional $7.0 billion in future milestones
Pasatru™ (garetosmab) approved by FDA for fibrodysplasia ossificans progressiva (FOP)

TARRYTOWN, N.Y., Oct. 30, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial results for the third quarter of 2026 and provided a business update.

“This was an outstanding quarter for Regeneron, with Dupixent, EYLEA HD, and Libtayo each achieving record net sales,” said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron. “Our pipeline of about 50 product candidates is rapidly advancing. We expect an FDA decision for cemdisiran in generalized myasthenia gravis next month; our Phase 3 programs in multiple myeloma, lymphoma, anticoagulation, and obesity continue to advance; and we have generated encouraging early data in MASH, POTS, and ovarian cancer. Finally, we expanded our alliance with Sanofi to include four Regeneron-invented, next-generation, long-acting antibodies designed to build on the success of Dupixent.”

Financial Highlights

($ in millions, except per share data)	Q3 2026		Q3 2025		% Change
Total revenues	$	5,116	$	3,754	36%
GAAP net income	$	1,949	$	1,460	33%
GAAP net income per share – diluted	$	18.45	$	13.62	35%
Non-GAAP net income^(a)	$	2,150	$	1,287	67%
Non-GAAP net income per share – diluted^(a)	$	20.07	$	11.83	70%

“We are pleased with our third quarter financial results, which marked our third consecutive quarter of double-digit growth in both revenue and non-GAAP EPS,” said Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer of Regeneron. “Strong commercial execution across our portfolio, together with the anticipated step-up in Sanofi collaboration revenue in the first full quarter following repayment of the Development Balance, drove a 36% increase in total revenues and a 70% increase in non-GAAP EPS, positioning us to deliver one of our strongest years ever.”

Business Highlights

Key Pipeline Progress
Regeneron has approximately 50 product candidates in clinical development, including a number of marketed products for which it is investigating additional indications. Updates from the clinical pipeline include:

Libtayo (cemiplimab)

In August 2026, the Ministry of Health, Labour and Welfare (MHLW) in Japan approved Libtayo as an adjuvant treatment for cutaneous squamous cell carcinoma (CSCC) and for the treatment of metastatic or locally advanced CSCC. These indications are already approved in the United States and European Union (EU).
In October 2026, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of an alternative dosing schedule for Libtayo across all approved indications. The positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after the first 12 weeks of treatment. The European Commission (EC) is expected to make a final decision in the coming months. There is also a supplemental Biologics License Application (sBLA) under review by the U.S. Food and Drug Administration (FDA), which has a target action date in March 2027.
In October 2026, the Company announced longer-term data which showed increasing and clinically meaningful overall survival benefit for Libtayo as an adjuvant treatment for patients with CSCC. The results were presented at the European Society for Medical Oncology (ESMO) 2026 Meeting.

Other Oncology Programs

The FDA accepted for review the resubmission of the BLA for Ordspono^™ (odronextamab) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), which has a target action date in February 2027.
The Company announced that ubamatamab (MUC16 and CD3 bispecific antibody) showed a high rate of durable responses in an initial study in patients with advanced low-grade serous ovarian cancer (LGSOC). The data are from an ongoing Phase 1/2 trial and were presented at the International Gynecologic Cancer Society (IGCS) 2026 Annual Global Meeting. Based on these preliminary trial results, the Company has been enrolling a single-arm, potentially registrational LGSOC trial and is planning to initiate a confirmatory Phase 3 trial in this setting.

Pasatru (garetosmab)

In August 2026, the FDA approved Pasatru to reduce formation of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP. A regulatory application is also under review in the EU.
The Company announced positive 84-week results from the Phase 3 trial for Pasatru in adults with FOP. These longer-term findings demonstrated sustained efficacy in halting new, rogue bone growth and in significantly reducing disease flare-ups, and were presented at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting.

Other Programs

A three-arm, placebo-controlled Phase 3 study was initiated to evaluate cenvacibart (an antibody to Factor XI (catalytic domain)), and amrecibart (an antibody to Factor XI (A2 domain)), individually, for the prevention of venous thromboembolism in patients with a peripherally inserted central catheter (PICC).
The Company has an ongoing Phase 1/2 study for its RNAi therapy targeting CIDEB. Interim results from this randomized, placebo-controlled, first-in-human trial in adults with metabolic dysfunction-associated steatotic liver disease (MASLD) showed that a single dose was generally well tolerated and reduced liver fat by approximately 70% on average from baseline at 12 weeks, with effects sustained through 24 weeks of follow-up. The Company plans to present interim results at the American Association for the Study of Liver Diseases (AASLD) Meeting in November 2026 and to initiate a Phase 3 study in metabolic dysfunction-associated steatohepatitis (MASH)/MASLD in the fourth quarter of 2026.
The Company plans to report results from the Phase 2 study for baloncibart (NPR1 antagonist antibody) in postural orthostatic tachycardia syndrome (POTS) at the American Autonomic Society (AAS) Meeting in November 2026. Additionally, the Company plans to initiate a Phase 3 study in POTS in the first half of 2027, pending regulatory feedback.
The Company announced new results from the Phase 2 COURAGE trial evaluating trevogrumab (myostatin antibody) for its potential to prevent lean mass and muscle loss during GLP-1 receptor agonist-induced weight loss in people living with obesity. The results of the trial were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting.
A second Phase 3 study was initiated for REGN1908-1909, an investigational treatment for cat allergy.

Corporate Updates

In October 2026, the Company and Sanofi amended their antibody collaboration, adding multiple next-generation, long-acting Regeneron-invented antibodies to the alliance. Under the terms of the agreement, the Company received an up-front payment of $1.0 billion, and is entitled to receive up to an additional $7.0 billion in the aggregate upon the achievement of certain development, regulatory, and sales-based milestones. The companies will equally share development and commercialization costs for the new programs, and, if commercialized, share any future profits equally on a global basis.
In October 2026, the Company announced an agreement with the Biomedical Advanced Research and Development Authority (BARDA) to provide additional supply of Inmazeb^® for U.S. preparedness against Ebola disease. Under the terms of the agreement, the Company expects to deliver a pre-specified number of treatment doses of Inmazeb each year to the U.S. government beginning in 2027 through 2031.

Third Quarter 2026 Financial Results

Revenues

($ in millions)	Q3 2026		Q3 2025		% Change
Net product sales:
EYLEA HD – U.S.	$	699	$	431	62%
EYLEA^® – U.S.		400		681	(41%	)
Total EYLEA HD and EYLEA – U.S.		1,099		1,112	(1%	)
Libtayo – U.S.		396		219	81%
Libtayo – ROW*		154		146	5%
Total Libtayo – Global		550		365	51%
Praluent^®– U.S.		81		67	21%
Evkeeza^®– U.S.		55		43	28%
Lynozyfic^®– Global		19		1	**
Other products – Global		1		—	**
Total net product sales		1,805		1,588	14%

Collaboration revenue:
Sanofi		2,724		1,617	68%
Bayer		267		345	(23%	)
Other		10		6	67%
Other revenue		310		198	57%
Total revenues	$	5,116	$	3,754	36%

* Rest of world (ROW)
** Percentage not meaningful or greater than 100%

EYLEA HD U.S. net product sales increased in the third quarter of 2026, compared to the third quarter of 2025, primarily due to higher sales volumes driven by increased demand, partly offset by a lower net selling price.

EYLEA U.S. net product sales decreased in the third quarter of 2026, compared to the third quarter of 2025, primarily due to lower sales volumes as a result of continued competitive pressures and the continued transition of patients to EYLEA HD.

Libtayo U.S. net product sales increased in the third quarter of 2026, compared to the third quarter of 2025, primarily due to higher sales volumes driven by increased demand.

Sanofi collaboration revenue increased in the third quarter of 2026, compared to the third quarter of 2025, due to an increase in the Company’s share of profits from the commercialization of antibodies, which were $2.575 billion and $1.456 billion in the third quarter of 2026 and 2025, respectively. The increase in the Company’s share of profits from the commercialization of antibodies was driven by higher profits primarily associated with an increase in Dupixent sales. In addition, the Sanofi Development Balance was fully repaid as of the end of the second quarter of 2026 and no longer reduced Sanofi collaboration revenue beginning in the third quarter of 2026.

Refer to Table 4 for a summary of collaboration revenue.

Operating Expenses

	GAAP					% Change		Non-GAAP^(a)				% Change
($ in millions)	Q3 2026		Q3 2025			% Change		Q3 2026		Q3 2025		% Change
Research and development (R&D)	$	1,795	$	1,475		22%		$	1,654	$	1,350	23%
Acquired in-process research and development (IPR&D)	$	22	$	83		(73%	)	*		*		*
Selling, general, and administrative (SG&A)	$	678	$	658		3%		$	588	$	541	9%
Cost of goods sold (COGS)	$	322	$	281		15%		$	246	$	227	8%
Gross margin on net product sales^(b)		82%		82%					86%		86%
Cost of collaboration and contract manufacturing (COCM)^(c)	$	252	$	241		5%		*		*		*
Other operating (income) expense, net	$	—	$	(10	)	(100%	)	*		*		*

* GAAP and non-GAAP amounts are equivalent as no non-GAAP adjustments have been recorded

GAAP and non-GAAP R&D expenses increased in the third quarter of 2026, compared to the third quarter of 2025, driven by the advancement of the Company’s clinical pipeline and increased manufacturing activity associated with the Company’s product candidates.

Other Financial Information

GAAP other income (expense), net decreased in the third quarter of 2026, compared to the third quarter of 2025, primarily due to lower net gains on marketable and other securities.

In the third quarter of 2026, the Company’s GAAP effective tax rate (ETR) was 14.7%, compared to 17.2% in the third quarter of 2025. The GAAP ETR for the third quarter of 2025 was negatively impacted by the enactment of the “One Big Beautiful Bill Act” or “OBBBA,” including a $45 million charge related to the re-measurement of the Company’s U.S. net deferred tax assets. In the third quarter of 2026, the non-GAAP ETR was 15.0%, compared to 13.1% in the third quarter of 2025.

A reconciliation of the Company’s GAAP to non-GAAP results is included in Table 3 of this press release.

Capital Allocation

During the nine months ended September 30, 2026, the Company repurchased $2.3 billion of its common stock. As of September 30, 2026, $2.2 billion remained available for share repurchases under the Company’s share repurchase programs.

In October 2026, the Company declared a cash dividend of $0.94 per share on the Company’s common stock and Class A stock, payable on December 3, 2026 to shareholders of record as of November 20, 2026.

2026 Financial Guidance*

The Company’s full year 2026 financial guidance consists of the following components:

	2026 Guidance
	Prior	Updated
GAAP R&D	$6.500–$6.635 billion	$6.600–$6.735 billion
Non-GAAP R&D^(a)	$5.950–$6.050 billion	$6.050–$6.150 billion
GAAP SG&A	$2.830–$2.960 billion	$2.730–$2.860 billion
Non-GAAP SG&A^(a)	$2.500–$2.600 billion	$2.400–$2.500 billion
GAAP gross margin on net product sales	78%–79%	Approximately 80%
Non-GAAP gross margin on net product sales^(a)	84%–85%	Approximately 86%
GAAP COCM	$985 million–$1.035 billion	Unchanged
Non-GAAP COCM^(a)	$970 million–$1.020 billion	Unchanged
Capital expenditures	$1.030–$1.100 billion	$1.050–$1.100 billion
GAAP effective tax rate	13%–14%	Approximately 14%
Non-GAAP effective tax rate^(a)	14%–15%	Approximately 15%

* The Company’s 2026 financial guidance does not assume the completion of any business development transactions not completed as of the date of this press release

A reconciliation of full year 2026 GAAP to non-GAAP financial guidance is included below:

	Projected Range
($ in millions)	Low			High
GAAP R&D	$	6,600		$	6,735
Stock-based compensation expense		(550	)		(580	)
Other		—			(5	)
Non-GAAP R&D^(a)	$	6,050		$	6,150

GAAP SG&A	$	2,730		$	2,860
Stock-based compensation expense		(325	)		(350	)
Other*		(5	)		(10	)
Non-GAAP SG&A^(a)	$	2,400		$	2,500

GAAP gross margin on net product sales		80%			80%
Stock-based compensation expense		1%			1%
Other**		5%			5%
Non-GAAP gross margin on net product sales^(a)		86%			86%

GAAP COCM	$	985		$	1,035
Temporary manufacturing interruption-related costs		(15	)		(15	)
Non-GAAP COCM^(a)	$	970		$	1,020

GAAP ETR		14%			14%
Income tax effect of GAAP to non-GAAP reconciling items		1%			1%
Income tax expense: Shortfall from stock-based compensation	(<1%		)	(<1%		)
Non-GAAP ETR^(a)		15%			15%

* Includes litigation settlements and other costs
** Includes intangible asset amortization and temporary manufacturing interruption-related costs

^(a)	This press release uses non-GAAP R&D, non-GAAP SG&A, non-GAAP COGS, non-GAAP gross margin on net product sales, non-GAAP COCM, non-GAAP other income (expense), net, non-GAAP ETR, non-GAAP net income, non-GAAP net income per share, and free cash flow, which are financial measures that are not calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP). These non-GAAP financial measures are computed by excluding certain non-cash and/or other items from the related GAAP financial measure. The Company also includes a non-GAAP adjustment for the estimated income tax effect of reconciling items. A reconciliation of the Company’s GAAP to non-GAAP results is included in Table 3 of this press release. The Company makes such adjustments for items the Company does not view as useful in evaluating its operating performance. For example, adjustments may be made for items that fluctuate from period to period based on factors that are not within the Company’s control (such as the Company’s stock price on the dates share-based grants are issued or changes in the fair value of the Company’s investments in equity securities) or items that are not associated with normal, recurring operations (such as acquisition and integration costs). Management uses these non-GAAP measures for planning, budgeting, forecasting, assessing historical performance, and making financial and operational decisions, and also provides forecasts to investors on this basis. With respect to free cash flow, the Company believes that this non-GAAP measure provides a further measure of the Company’s ability to generate cash flows from its operations. Additionally, the non-GAAP measures presented are intended to provide investors with an enhanced understanding of the financial performance of the Company’s core business operations. However, there are limitations in the use of these and other non-GAAP financial measures as they exclude certain expenses that are recurring in nature. Furthermore, the Company’s non-GAAP financial measures may not be comparable with non-GAAP information provided by other companies. Any non-GAAP financial measure presented by the Company should be considered supplemental to, and not a substitute for, measures of financial performance prepared in accordance with GAAP.

^(b)	Gross margin on net product sales represents gross profit expressed as a percentage of total net product sales recorded by the Company. Gross profit is calculated as net product sales less cost of goods sold.

^(c)	Corresponding reimbursements from collaborators and others for manufacturing product is recorded within revenues.

Conference Call Information

Regeneron will host a conference call and simultaneous webcast to discuss its third quarter 2026 financial and operating results on Friday, October 30, 2026, at 8:30 AM Eastern Time. Participants may access the conference call live via webcast, or register in advance and participate via telephone, on the “Investors and Media” page of Regeneron’s website at www.regeneron.com. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay and transcript of the conference call and webcast will be archived on the Company’s website for at least 30 days.

About Regeneron

Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, Regeneron’s unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in Regeneron’s laboratories. Regeneron’s medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using its proprietary technologies, such as VelociSuite^®, which produces optimized fully human antibodies and new classes of bispecific antibodies. Regeneron is shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center^® and pioneering genetic medicine platforms, enabling Regeneron to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit www.regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook, or X.

Forward-Looking Statements and Use of Digital Media

This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”); uncertainty of the utilization, market acceptance, and commercial success of Regeneron’s Products and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) or recommendations and guidelines from governmental authorities and other third parties or other factors beyond Regeneron’s control on the commercial success of Regeneron’s Products and Regeneron’s Product Candidates; the nature, timing, and possible success and therapeutic applications of Regeneron’s Products and Regeneron’s Product Candidates and research and clinical programs now underway or planned, including without limitation EYLEA HD^® (aflibercept) Injection 8 mg, EYLEA^® (aflibercept) Injection, Dupixent^® (dupilumab), Libtayo^® (cemiplimab), Praluent^® (alirocumab), Kevzara^® (sarilumab), Evkeeza^® (evinacumab), Veopoz^® (pozelimab), Ordspono^™ (odronextamab), Lynozyfic^® (linvoseltamab), Otarmeni^® (lunsotogene parvec), Pasatru^™(garetosmab), other clinical programs discussed in this press release, Regeneron’s and its collaborators’ earlier-stage programs, and the use of human genetics in Regeneron’s research programs; the likelihood and timing of achieving any of the anticipated milestones described in this press release; safety issues resulting from the administration of Regeneron’s Products and Regeneron’s Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products, including those listed above and/or otherwise discussed in this press release; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; the ability of Regeneron’s collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes to drug pricing regulations and requirements and Regeneron’s drug pricing strategy, including in connection with Regeneron’s April 2026 agreements with the U.S. government; other changes in laws, regulations, and policies affecting the healthcare industry; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance, including GAAP and non-GAAP R&D, GAAP and non-GAAP SG&A, GAAP and non-GAAP gross margin on net product sales, GAAP and non-GAAP COCM, capital expenditures, and GAAP and non-GAAP ETR; the potential for any license or collaboration agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron’s business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney’s Office for the District of Massachusetts), risks associated with intellectual property of the Company or other parties and pending or future litigation or patent office proceedings relating thereto (including without limitation patent litigation and other related proceedings relating to Regeneron’s Products), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the fiscal year ended December 31, 2025 and its Form 10-Q for the quarterly period ended September 30, 2026. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron’s media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).

Non-GAAP Financial Measures

This press release and/or the financial results attached to this press release include amounts that are considered “non-GAAP financial measures” under SEC rules. As required, Regeneron has provided reconciliations of such non-GAAP financial measures.

	Contact Information:

	Ryan Crowe		Christina Chan
	Investor Relations		Corporate Affairs
	914-847-8790		914-847-8827
	ryan.crowe@regeneron.com		christina.chan@regeneron.com

TABLE 1

REGENERON PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) *(In millions)*

	September 30,		December 31,
	2026		2025
Assets:
Cash and marketable securities	$	18,858.5	$	18,865.8
Accounts receivable, net		7,578.6		5,741.1
Inventories		2,894.6		3,200.8
Property, plant, and equipment, net		5,727.5		5,120.4
Intangible assets, net		1,315.5		1,257.4
Deferred tax assets		4,535.6		4,077.2
Other assets		3,494.9		2,296.0
Total assets	$	44,405.2	$	40,558.7

Liabilities and stockholders’ equity:
Accounts payable, accrued expenses, and other liabilities	$	7,229.7	$	5,834.2
Finance lease liabilities		720.0		720.0
Deferred revenue		970.0		761.7
Long-term debt		1,987.0		1,985.9
Stockholders’ equity		33,498.5		31,256.9
Total liabilities and stockholders’ equity	$	44,405.2	$	40,558.7

TABLE 2

REGENERON PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In millions, except per share data)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2026			2025			2026			2025
Revenues:
Net product sales	$	1,805.3		$	1,587.7		$	4,982.2		$	4,634.3
Collaboration revenue		3,000.5			1,968.4			7,355.2			5,360.3
Other revenue		310.0			198.2			674.5			464.0
		5,115.8			3,754.3			13,011.9			10,458.6
Expenses:
Research and development		1,794.7			1,475.0			4,969.8			4,224.1
Acquired in-process research and development		21.5			83.1			250.4			105.4
Selling, general, and administrative		677.8			657.8			1,987.6			1,925.0
Cost of goods sold		321.7			281.0			1,055.8			822.1
Cost of collaboration and contract manufacturing		251.9			240.6			763.7			694.0
Other operating (income) expense, net		—			(10.0	)		—			(10.0	)
		3,067.6			2,727.5			9,027.3			7,760.6

Income from operations		2,048.2			1,026.8			3,984.6			2,698.0

Other income (expense):
Other income (expense), net		246.5			755.8			693.0			1,520.6
Interest expense		(10.6	)		(19.3	)		(34.5	)		(31.6	)
		235.9			736.5			658.5			1,489.0

Income before income taxes		2,284.1			1,763.3			4,643.1			4,187.0

Income tax expense		335.4			303.3			670.3			526.7

Net income	$	1,948.7		$	1,460.0		$	3,972.8		$	3,660.3

Net income per share – basic	$	19.16		$	14.09		$	38.65		$	34.83
Net income per share – diluted	$	18.45		$	13.62		$	37.37		$	33.61

Weighted average shares outstanding – basic		101.7			103.6			102.8			105.1
Weighted average shares outstanding – diluted		105.6			107.2			106.3			108.9

TABLE 3

REGENERON PHARMACEUTICALS, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (Unaudited) *(In millions, except per share data)*

	Three Months Ended September 30,						Nine Months Ended September 30,
	2026			2025			2026			2025
GAAP R&D	$	1,794.7		$	1,475.0		$	4,969.8		$	4,224.1
Stock-based compensation expense		(140.3	)		(125.1	)		(406.2	)		(405.1	)
Other costs		(0.6	)		—			(1.2	)		—
Non-GAAP R&D	$	1,653.8		$	1,349.9		$	4,562.4		$	3,819.0

GAAP SG&A	$	677.8		$	657.8		$	1,987.6		$	1,925.0
Stock-based compensation expense		(86.6	)		(92.0	)		(261.3	)		(279.0	)
Litigation settlements		—			(25.0	)		5.0			(25.0	)
Other costs		(2.9	)		—			(8.8	)		(0.8	)
Non-GAAP SG&A	$	588.3		$	540.8		$	1,722.5		$	1,620.2

GAAP COGS	$	321.7		$	281.0		$	1,055.8		$	822.1
Stock-based compensation expense		(28.9	)		(19.9	)		(88.7	)		(60.3	)
Intangible asset amortization expense		(47.1	)		(33.7	)		(130.3	)		(94.8	)
Temporary manufacturing interruption-related costs		—			—			(161.3	)		—
Non-GAAP COGS	$	245.7		$	227.4		$	675.5		$	667.0

GAAP COCM	$	251.9		$	240.6		$	763.7		$	694.0
Temporary manufacturing interruption-related costs		—			—			(14.8	)		—
Non-GAAP COCM	$	251.9		$	240.6		$	748.9		$	694.0

GAAP other income (expense), net	$	235.9		$	736.5		$	658.5		$	1,489.0
Gains on marketable and other securities, net		(60.3	)		(577.7	)		(147.2	)		(967.6	)
Non-GAAP other income (expense), net	$	175.6		$	158.8		$	511.3		$	521.4

GAAP net income	$	1,948.7		$	1,460.0		$	3,972.8		$	3,660.3
Total of GAAP to non-GAAP reconciling items above		246.1			(282.0	)		920.4			(102.6	)
Income tax effect of GAAP to non-GAAP reconciling items		(48.8	)		64.7			(170.6	)		37.0
Income tax expense: Shortfall from stock-based compensation		4.0			—			10.1			—
Income tax expense: Charge related to enactment of OBBBA		—			44.5			—			44.5
Non-GAAP net income	$	2,150.0		$	1,287.2		$	4,732.7		$	3,639.2

Non-GAAP net income per share – basic	$	21.14		$	12.42		$	46.04		$	34.63
Non-GAAP net income per share – diluted	$	20.07		$	11.83		$	43.70		$	32.87

Shares used in calculating:
Non-GAAP net income per share – basic		101.7			103.6			102.8			105.1
Non-GAAP net income per share – diluted		107.1			108.8			108.3			110.7

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (Unaudited) (continued)

	Three Months Ended September 30,					Nine Months Ended September 30,
	2026		2025			2026			2025
Effective tax rate reconciliation:
GAAP ETR	14.7%			17.2%			14.4%		12.6%
Income tax effect of GAAP to non-GAAP reconciling items	0.4%			(2.4%	)		0.6%		(0.8%	)
Income tax expense: Shortfall from stock-based compensation	(0.1%	)		—%			(0.1%	)	—%
Income tax expense: Charge related to enactment of OBBBA	—%			(1.7%	)		—%		(0.9%	)
Non-GAAP ETR	15.0%			13.1%			14.9%		10.9%

Gross margin on net product sales reconciliation:
GAAP gross margin on net product sales	82%			82%			79%		82%
Stock-based compensation expense	2%			2%			2%		2%
Intangible asset amortization expense	2%			2%			2%		2%
Temporary manufacturing interruption-related costs	—%			—%			3%		—%
Non-GAAP gross margin on net product sales	86%			86%			86%		86%

			Nine Months Ended September 30,
			2026			2025
Free cash flow reconciliation:
Net cash provided by operating activities			$	3,675.3		$	3,808.2
Capital expenditures				(771.0	)		(649.7	)
Free cash flow			$	2,904.3		$	3,158.5

TABLE 4

REGENERON PHARMACEUTICALS, INC. COLLABORATION REVENUE (Unaudited) *(In millions)*

	Three Months Ended September 30,				Nine Months Ended September 30,
	2026		2025		2026		2025
Sanofi collaboration revenue:
Regeneron’s share of profits in connection with commercialization of antibodies	$	2,574.9	$	1,455.5	$	6,058.3	$	3,755.7
Reimbursement for manufacturing of commercial supplies		149.1		161.5		445.1		488.1
Total Sanofi collaboration revenue		2,724.0		1,617.0		6,503.4		4,243.8

Bayer collaboration revenue:
Regeneron’s share of profits in connection with commercialization of EYLEA 8 mg and EYLEA outside the United States		211.5		311.9		678.8		1,012.6
Reimbursement for manufacturing of commercial supplies		55.3		32.9		151.5		91.1
Total Bayer collaboration revenue		266.8		344.8		830.3		1,103.7

Other collaboration revenue		9.7		6.6		21.5		12.8

Total collaboration revenue	$	3,000.5	$	1,968.4	$	7,355.2	$	5,360.3

TABLE 5

REGENERON PHARMACEUTICALS, INC. NET PRODUCT SALES OF REGENERON-DISCOVERED PRODUCTS (Unaudited) *(In millions)*

	Three Months Ended September 30,
	2026						2025						% Change
	U.S.		ROW		Total		U.S.		ROW		Total		(Total Sales)
Dupixent^(a)	$	5,064.1	$	1,476.4	$	6,540.5	$	3,618.8	$	1,238.2	$	4,857.0	35%
EYLEA HD^(b)	$	698.8	$	384.0	$	1,082.8	$	430.6	$	232.4	$	663.0	63%
EYLEA^(b)	$	399.7	$	258.7	$	658.4	$	680.6	$	621.4	$	1,302.0	(49%	)
Total EYLEA HD and EYLEA	$	1,098.5	$	642.7	$	1,741.2	$	1,111.2	$	853.8	$	1,965.0	(11%	)
Libtayo^(c)	$	395.8	$	154.2	$	550.0	$	219.1	$	146.1	$	365.2	51%
Praluent^(d)	$	81.5	$	179.4	$	260.9	$	67.7	$	148.0	$	215.7	21%
Kevzara^(a)	$	192.7	$	62.9	$	255.6	$	102.9	$	51.1	$	154.0	66%
Lynozyfic	$	18.6	$	0.4	$	19.0	$	0.8	$	—	$	0.8	*
Other products^(e)	$	56.2	$	35.1	$	91.3	$	43.1	$	28.0	$	71.1	28%

	Nine Months Ended September 30,
	2026						2025						% Change
	U.S.		ROW		Total		U.S.		ROW		Total		(Total Sales)
Dupixent^(a)	$	13,183.6	$	4,235.2	$	17,418.8	$	9,453.2	$	3,414.0	$	12,867.2	35%
EYLEA HD^(b)	$	1,763.5	$	1,082.8	$	2,846.3	$	1,130.6	$	620.5	$	1,751.1	63%
EYLEA^(b)	$	1,285.0	$	955.1	$	2,240.1	$	2,170.9	$	2,068.8	$	4,239.7	(47%	)
Total EYLEA HD and EYLEA	$	3,048.5	$	2,037.9	$	5,086.4	$	3,301.5	$	2,689.3	$	5,990.8	(15%	)
Libtayo^(c)	$	1,024.5	$	453.1	$	1,477.6	$	659.4	$	367.4	$	1,026.8	44%
Praluent^(d)	$	222.8	$	549.4	$	772.2	$	190.3	$	440.7	$	631.0	22%
Kevzara^(a)	$	436.6	$	169.7	$	606.3	$	271.4	$	151.2	$	422.6	43%
Lynozyfic	$	45.5	$	1.2	$	46.7	$	0.8	$	—	$	0.8	*
Other products^(e)	$	187.3	$	95.0	$	282.3	$	116.3	$	81.5	$	197.8	43%

Note: The table above includes net product sales of Regeneron-discovered products. Such net product sales are recorded by the Company or others, as further described in the footnotes below.
* Percentage not meaningful or greater than 100%
^(a) Sanofi records global net product sales of Dupixent and Kevzara, and the Company records its share of profits in connection with global sales of such products within Collaboration revenue
^(b) The Company records net product sales of EYLEA HD and EYLEA in the United States, and Bayer records net product sales outside the United States. The Company records its share of profits in connection with sales outside the United States within Collaboration revenue.
^(c) The Company records global net product sales of Libtayo and pays Sanofi a royalty on such sales
^(d) The Company records net product sales of Praluent in the United States. Sanofi records net product sales of Praluent outside the United States and pays the Company a royalty on such sales, which is recorded within Other revenue.
^(e) Included in this line item are products which are sold by the Company and others. Refer to “Third Quarter 2026 Financial Results” section above for a listing of net product sales recorded by the Company. Not included in this line item are net product sales of ARCALYST^®, which are recorded by Kiniksa.

Posted in UncategorizedTagged GlobeNewswire

Regeneron Reports Third Quarter 2026 Financial and Operating Results

Posted on October 30, 2026 by Ravi Shankar

Third quarter 2026 revenues increased 36% to $5.1 billion versus third quarter 2025
Dupixent^® global net sales (recorded by Sanofi) increased 35% to $6.5 billion
EYLEA HD^®U.S. net sales increased 62% to $699 million
Libtayo^® global net sales increased 51% to $550 million
GAAP EPS increased 35% to $18.45; non-GAAP EPS^(a)increased 70% to $20.07
Expanded collaboration with Sanofi, adding multiple next-generation, long-acting immunology antibodies; $1.0 billion up-front to be recognized as collaboration revenue in fourth quarter 2026 with potential to receive up to an additional $7.0 billion in future milestones
Pasatru™ (garetosmab) approved by FDA for fibrodysplasia ossificans progressiva (FOP)

TARRYTOWN, N.Y., Oct. 30, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial results for the third quarter of 2026 and provided a business update.

Financial Highlights

($ in millions, except per share data)	Q3 2026		Q3 2025		% Change
Total revenues	$	5,116	$	3,754	36%
GAAP net income	$	1,949	$	1,460	33%
GAAP net income per share – diluted	$	18.45	$	13.62	35%
Non-GAAP net income^(a)	$	2,150	$	1,287	67%
Non-GAAP net income per share – diluted^(a)	$	20.07	$	11.83	70%

Business Highlights

Libtayo (cemiplimab)

In August 2026, the Ministry of Health, Labour and Welfare (MHLW) in Japan approved Libtayo as an adjuvant treatment for cutaneous squamous cell carcinoma (CSCC) and for the treatment of metastatic or locally advanced CSCC. These indications are already approved in the United States and European Union (EU).
In October 2026, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of an alternative dosing schedule for Libtayo across all approved indications. The positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after the first 12 weeks of treatment. The European Commission (EC) is expected to make a final decision in the coming months. There is also a supplemental Biologics License Application (sBLA) under review by the U.S. Food and Drug Administration (FDA), which has a target action date in March 2027.
In October 2026, the Company announced longer-term data which showed increasing and clinically meaningful overall survival benefit for Libtayo as an adjuvant treatment for patients with CSCC. The results were presented at the European Society for Medical Oncology (ESMO) 2026 Meeting.

Other Oncology Programs

The FDA accepted for review the resubmission of the BLA for Ordspono^™ (odronextamab) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), which has a target action date in February 2027.
The Company announced that ubamatamab (MUC16 and CD3 bispecific antibody) showed a high rate of durable responses in an initial study in patients with advanced low-grade serous ovarian cancer (LGSOC). The data are from an ongoing Phase 1/2 trial and were presented at the International Gynecologic Cancer Society (IGCS) 2026 Annual Global Meeting. Based on these preliminary trial results, the Company has been enrolling a single-arm, potentially registrational LGSOC trial and is planning to initiate a confirmatory Phase 3 trial in this setting.

Pasatru (garetosmab)

In August 2026, the FDA approved Pasatru to reduce formation of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP. A regulatory application is also under review in the EU.
The Company announced positive 84-week results from the Phase 3 trial for Pasatru in adults with FOP. These longer-term findings demonstrated sustained efficacy in halting new, rogue bone growth and in significantly reducing disease flare-ups, and were presented at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting.

Other Programs

A three-arm, placebo-controlled Phase 3 study was initiated to evaluate cenvacibart (an antibody to Factor XI (catalytic domain)), and amrecibart (an antibody to Factor XI (A2 domain)), individually, for the prevention of venous thromboembolism in patients with a peripherally inserted central catheter (PICC).
The Company has an ongoing Phase 1/2 study for its RNAi therapy targeting CIDEB. Interim results from this randomized, placebo-controlled, first-in-human trial in adults with metabolic dysfunction-associated steatotic liver disease (MASLD) showed that a single dose was generally well tolerated and reduced liver fat by approximately 70% on average from baseline at 12 weeks, with effects sustained through 24 weeks of follow-up. The Company plans to present interim results at the American Association for the Study of Liver Diseases (AASLD) Meeting in November 2026 and to initiate a Phase 3 study in metabolic dysfunction-associated steatohepatitis (MASH)/MASLD in the fourth quarter of 2026.
The Company plans to report results from the Phase 2 study for baloncibart (NPR1 antagonist antibody) in postural orthostatic tachycardia syndrome (POTS) at the American Autonomic Society (AAS) Meeting in November 2026. Additionally, the Company plans to initiate a Phase 3 study in POTS in the first half of 2027, pending regulatory feedback.
The Company announced new results from the Phase 2 COURAGE trial evaluating trevogrumab (myostatin antibody) for its potential to prevent lean mass and muscle loss during GLP-1 receptor agonist-induced weight loss in people living with obesity. The results of the trial were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting.
A second Phase 3 study was initiated for REGN1908-1909, an investigational treatment for cat allergy.

Corporate Updates

In October 2026, the Company and Sanofi amended their antibody collaboration, adding multiple next-generation, long-acting Regeneron-invented antibodies to the alliance. Under the terms of the agreement, the Company received an up-front payment of $1.0 billion, and is entitled to receive up to an additional $7.0 billion in the aggregate upon the achievement of certain development, regulatory, and sales-based milestones. The companies will equally share development and commercialization costs for the new programs, and, if commercialized, share any future profits equally on a global basis.
In October 2026, the Company announced an agreement with the Biomedical Advanced Research and Development Authority (BARDA) to provide additional supply of Inmazeb^® for U.S. preparedness against Ebola disease. Under the terms of the agreement, the Company expects to deliver a pre-specified number of treatment doses of Inmazeb each year to the U.S. government beginning in 2027 through 2031.

Third Quarter 2026 Financial Results

Revenues

($ in millions)	Q3 2026		Q3 2025		% Change
Net product sales:
EYLEA HD – U.S.	$	699	$	431	62%
EYLEA^® – U.S.		400		681	(41%	)
Total EYLEA HD and EYLEA – U.S.		1,099		1,112	(1%	)
Libtayo – U.S.		396		219	81%
Libtayo – ROW*		154		146	5%
Total Libtayo – Global		550		365	51%
Praluent^®– U.S.		81		67	21%
Evkeeza^®– U.S.		55		43	28%
Lynozyfic^®– Global		19		1	**
Other products – Global		1		—	**
Total net product sales		1,805		1,588	14%

Collaboration revenue:
Sanofi		2,724		1,617	68%
Bayer		267		345	(23%	)
Other		10		6	67%
Other revenue		310		198	57%
Total revenues	$	5,116	$	3,754	36%

* Rest of world (ROW)
** Percentage not meaningful or greater than 100%

Libtayo U.S. net product sales increased in the third quarter of 2026, compared to the third quarter of 2025, primarily due to higher sales volumes driven by increased demand.

Refer to Table 4 for a summary of collaboration revenue.

Operating Expenses

	GAAP					% Change		Non-GAAP^(a)				% Change
($ in millions)	Q3 2026		Q3 2025			% Change		Q3 2026		Q3 2025		% Change
Research and development (R&D)	$	1,795	$	1,475		22%		$	1,654	$	1,350	23%
Acquired in-process research and development (IPR&D)	$	22	$	83		(73%	)	*		*		*
Selling, general, and administrative (SG&A)	$	678	$	658		3%		$	588	$	541	9%
Cost of goods sold (COGS)	$	322	$	281		15%		$	246	$	227	8%
Gross margin on net product sales^(b)		82%		82%					86%		86%
Cost of collaboration and contract manufacturing (COCM)^(c)	$	252	$	241		5%		*		*		*
Other operating (income) expense, net	$	—	$	(10	)	(100%	)	*		*		*

* GAAP and non-GAAP amounts are equivalent as no non-GAAP adjustments have been recorded

Other Financial Information

GAAP other income (expense), net decreased in the third quarter of 2026, compared to the third quarter of 2025, primarily due to lower net gains on marketable and other securities.

A reconciliation of the Company’s GAAP to non-GAAP results is included in Table 3 of this press release.

Capital Allocation

2026 Financial Guidance*

The Company’s full year 2026 financial guidance consists of the following components:

	2026 Guidance
	Prior	Updated
GAAP R&D	$6.500–$6.635 billion	$6.600–$6.735 billion
Non-GAAP R&D^(a)	$5.950–$6.050 billion	$6.050–$6.150 billion
GAAP SG&A	$2.830–$2.960 billion	$2.730–$2.860 billion
Non-GAAP SG&A^(a)	$2.500–$2.600 billion	$2.400–$2.500 billion
GAAP gross margin on net product sales	78%–79%	Approximately 80%
Non-GAAP gross margin on net product sales^(a)	84%–85%	Approximately 86%
GAAP COCM	$985 million–$1.035 billion	Unchanged
Non-GAAP COCM^(a)	$970 million–$1.020 billion	Unchanged
Capital expenditures	$1.030–$1.100 billion	$1.050–$1.100 billion
GAAP effective tax rate	13%–14%	Approximately 14%
Non-GAAP effective tax rate^(a)	14%–15%	Approximately 15%

* The Company’s 2026 financial guidance does not assume the completion of any business development transactions not completed as of the date of this press release

A reconciliation of full year 2026 GAAP to non-GAAP financial guidance is included below:

	Projected Range
($ in millions)	Low			High
GAAP R&D	$	6,600		$	6,735
Stock-based compensation expense		(550	)		(580	)
Other		—			(5	)
Non-GAAP R&D^(a)	$	6,050		$	6,150

GAAP SG&A	$	2,730		$	2,860
Stock-based compensation expense		(325	)		(350	)
Other*		(5	)		(10	)
Non-GAAP SG&A^(a)	$	2,400		$	2,500

GAAP gross margin on net product sales		80%			80%
Stock-based compensation expense		1%			1%
Other**		5%			5%
Non-GAAP gross margin on net product sales^(a)		86%			86%

GAAP COCM	$	985		$	1,035
Temporary manufacturing interruption-related costs		(15	)		(15	)
Non-GAAP COCM^(a)	$	970		$	1,020

GAAP ETR		14%			14%
Income tax effect of GAAP to non-GAAP reconciling items		1%			1%
Income tax expense: Shortfall from stock-based compensation	(<1%		)	(<1%		)
Non-GAAP ETR^(a)		15%			15%

* Includes litigation settlements and other costs
** Includes intangible asset amortization and temporary manufacturing interruption-related costs

^(a)	This press release uses non-GAAP R&D, non-GAAP SG&A, non-GAAP COGS, non-GAAP gross margin on net product sales, non-GAAP COCM, non-GAAP other income (expense), net, non-GAAP ETR, non-GAAP net income, non-GAAP net income per share, and free cash flow, which are financial measures that are not calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP). These non-GAAP financial measures are computed by excluding certain non-cash and/or other items from the related GAAP financial measure. The Company also includes a non-GAAP adjustment for the estimated income tax effect of reconciling items. A reconciliation of the Company’s GAAP to non-GAAP results is included in Table 3 of this press release. The Company makes such adjustments for items the Company does not view as useful in evaluating its operating performance. For example, adjustments may be made for items that fluctuate from period to period based on factors that are not within the Company’s control (such as the Company’s stock price on the dates share-based grants are issued or changes in the fair value of the Company’s investments in equity securities) or items that are not associated with normal, recurring operations (such as acquisition and integration costs). Management uses these non-GAAP measures for planning, budgeting, forecasting, assessing historical performance, and making financial and operational decisions, and also provides forecasts to investors on this basis. With respect to free cash flow, the Company believes that this non-GAAP measure provides a further measure of the Company’s ability to generate cash flows from its operations. Additionally, the non-GAAP measures presented are intended to provide investors with an enhanced understanding of the financial performance of the Company’s core business operations. However, there are limitations in the use of these and other non-GAAP financial measures as they exclude certain expenses that are recurring in nature. Furthermore, the Company’s non-GAAP financial measures may not be comparable with non-GAAP information provided by other companies. Any non-GAAP financial measure presented by the Company should be considered supplemental to, and not a substitute for, measures of financial performance prepared in accordance with GAAP.

^(b)	Gross margin on net product sales represents gross profit expressed as a percentage of total net product sales recorded by the Company. Gross profit is calculated as net product sales less cost of goods sold.

^(c)	Corresponding reimbursements from collaborators and others for manufacturing product is recorded within revenues.

Conference Call Information

About Regeneron

For more information, please visit www.regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook, or X.

Forward-Looking Statements and Use of Digital Media

Non-GAAP Financial Measures

	Contact Information:

	Ryan Crowe		Christina Chan
	Investor Relations		Corporate Affairs
	914-847-8790		914-847-8827
	ryan.crowe@regeneron.com		christina.chan@regeneron.com

TABLE 1

REGENERON PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) *(In millions)*

	September 30,		December 31,
	2026		2025
Assets:
Cash and marketable securities	$	18,858.5	$	18,865.8
Accounts receivable, net		7,578.6		5,741.1
Inventories		2,894.6		3,200.8
Property, plant, and equipment, net		5,727.5		5,120.4
Intangible assets, net		1,315.5		1,257.4
Deferred tax assets		4,535.6		4,077.2
Other assets		3,494.9		2,296.0
Total assets	$	44,405.2	$	40,558.7

Liabilities and stockholders’ equity:
Accounts payable, accrued expenses, and other liabilities	$	7,229.7	$	5,834.2
Finance lease liabilities		720.0		720.0
Deferred revenue		970.0		761.7
Long-term debt		1,987.0		1,985.9
Stockholders’ equity		33,498.5		31,256.9
Total liabilities and stockholders’ equity	$	44,405.2	$	40,558.7

TABLE 2

REGENERON PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In millions, except per share data)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2026			2025			2026			2025
Revenues:
Net product sales	$	1,805.3		$	1,587.7		$	4,982.2		$	4,634.3
Collaboration revenue		3,000.5			1,968.4			7,355.2			5,360.3
Other revenue		310.0			198.2			674.5			464.0
		5,115.8			3,754.3			13,011.9			10,458.6
Expenses:
Research and development		1,794.7			1,475.0			4,969.8			4,224.1
Acquired in-process research and development		21.5			83.1			250.4			105.4
Selling, general, and administrative		677.8			657.8			1,987.6			1,925.0
Cost of goods sold		321.7			281.0			1,055.8			822.1
Cost of collaboration and contract manufacturing		251.9			240.6			763.7			694.0
Other operating (income) expense, net		—			(10.0	)		—			(10.0	)
		3,067.6			2,727.5			9,027.3			7,760.6

Income from operations		2,048.2			1,026.8			3,984.6			2,698.0

Other income (expense):
Other income (expense), net		246.5			755.8			693.0			1,520.6
Interest expense		(10.6	)		(19.3	)		(34.5	)		(31.6	)
		235.9			736.5			658.5			1,489.0

Income before income taxes		2,284.1			1,763.3			4,643.1			4,187.0

Income tax expense		335.4			303.3			670.3			526.7

Net income	$	1,948.7		$	1,460.0		$	3,972.8		$	3,660.3

Net income per share – basic	$	19.16		$	14.09		$	38.65		$	34.83
Net income per share – diluted	$	18.45		$	13.62		$	37.37		$	33.61

Weighted average shares outstanding – basic		101.7			103.6			102.8			105.1
Weighted average shares outstanding – diluted		105.6			107.2			106.3			108.9

TABLE 3

REGENERON PHARMACEUTICALS, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (Unaudited) *(In millions, except per share data)*

	Three Months Ended September 30,						Nine Months Ended September 30,
	2026			2025			2026			2025
GAAP R&D	$	1,794.7		$	1,475.0		$	4,969.8		$	4,224.1
Stock-based compensation expense		(140.3	)		(125.1	)		(406.2	)		(405.1	)
Other costs		(0.6	)		—			(1.2	)		—
Non-GAAP R&D	$	1,653.8		$	1,349.9		$	4,562.4		$	3,819.0

GAAP SG&A	$	677.8		$	657.8		$	1,987.6		$	1,925.0
Stock-based compensation expense		(86.6	)		(92.0	)		(261.3	)		(279.0	)
Litigation settlements		—			(25.0	)		5.0			(25.0	)
Other costs		(2.9	)		—			(8.8	)		(0.8	)
Non-GAAP SG&A	$	588.3		$	540.8		$	1,722.5		$	1,620.2

GAAP COGS	$	321.7		$	281.0		$	1,055.8		$	822.1
Stock-based compensation expense		(28.9	)		(19.9	)		(88.7	)		(60.3	)
Intangible asset amortization expense		(47.1	)		(33.7	)		(130.3	)		(94.8	)
Temporary manufacturing interruption-related costs		—			—			(161.3	)		—
Non-GAAP COGS	$	245.7		$	227.4		$	675.5		$	667.0

GAAP COCM	$	251.9		$	240.6		$	763.7		$	694.0
Temporary manufacturing interruption-related costs		—			—			(14.8	)		—
Non-GAAP COCM	$	251.9		$	240.6		$	748.9		$	694.0

GAAP other income (expense), net	$	235.9		$	736.5		$	658.5		$	1,489.0
Gains on marketable and other securities, net		(60.3	)		(577.7	)		(147.2	)		(967.6	)
Non-GAAP other income (expense), net	$	175.6		$	158.8		$	511.3		$	521.4

GAAP net income	$	1,948.7		$	1,460.0		$	3,972.8		$	3,660.3
Total of GAAP to non-GAAP reconciling items above		246.1			(282.0	)		920.4			(102.6	)
Income tax effect of GAAP to non-GAAP reconciling items		(48.8	)		64.7			(170.6	)		37.0
Income tax expense: Shortfall from stock-based compensation		4.0			—			10.1			—
Income tax expense: Charge related to enactment of OBBBA		—			44.5			—			44.5
Non-GAAP net income	$	2,150.0		$	1,287.2		$	4,732.7		$	3,639.2

Non-GAAP net income per share – basic	$	21.14		$	12.42		$	46.04		$	34.63
Non-GAAP net income per share – diluted	$	20.07		$	11.83		$	43.70		$	32.87

Shares used in calculating:
Non-GAAP net income per share – basic		101.7			103.6			102.8			105.1
Non-GAAP net income per share – diluted		107.1			108.8			108.3			110.7

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (Unaudited) (continued)

	Three Months Ended September 30,					Nine Months Ended September 30,
	2026		2025			2026			2025
Effective tax rate reconciliation:
GAAP ETR	14.7%			17.2%			14.4%		12.6%
Income tax effect of GAAP to non-GAAP reconciling items	0.4%			(2.4%	)		0.6%		(0.8%	)
Income tax expense: Shortfall from stock-based compensation	(0.1%	)		—%			(0.1%	)	—%
Income tax expense: Charge related to enactment of OBBBA	—%			(1.7%	)		—%		(0.9%	)
Non-GAAP ETR	15.0%			13.1%			14.9%		10.9%

Gross margin on net product sales reconciliation:
GAAP gross margin on net product sales	82%			82%			79%		82%
Stock-based compensation expense	2%			2%			2%		2%
Intangible asset amortization expense	2%			2%			2%		2%
Temporary manufacturing interruption-related costs	—%			—%			3%		—%
Non-GAAP gross margin on net product sales	86%			86%			86%		86%

			Nine Months Ended September 30,
			2026			2025
Free cash flow reconciliation:
Net cash provided by operating activities			$	3,675.3		$	3,808.2
Capital expenditures				(771.0	)		(649.7	)
Free cash flow			$	2,904.3		$	3,158.5

TABLE 4

REGENERON PHARMACEUTICALS, INC. COLLABORATION REVENUE (Unaudited) *(In millions)*

	Three Months Ended September 30,				Nine Months Ended September 30,
	2026		2025		2026		2025
Sanofi collaboration revenue:
Regeneron’s share of profits in connection with commercialization of antibodies	$	2,574.9	$	1,455.5	$	6,058.3	$	3,755.7
Reimbursement for manufacturing of commercial supplies		149.1		161.5		445.1		488.1
Total Sanofi collaboration revenue		2,724.0		1,617.0		6,503.4		4,243.8

Bayer collaboration revenue:
Regeneron’s share of profits in connection with commercialization of EYLEA 8 mg and EYLEA outside the United States		211.5		311.9		678.8		1,012.6
Reimbursement for manufacturing of commercial supplies		55.3		32.9		151.5		91.1
Total Bayer collaboration revenue		266.8		344.8		830.3		1,103.7

Other collaboration revenue		9.7		6.6		21.5		12.8

Total collaboration revenue	$	3,000.5	$	1,968.4	$	7,355.2	$	5,360.3

TABLE 5

REGENERON PHARMACEUTICALS, INC. NET PRODUCT SALES OF REGENERON-DISCOVERED PRODUCTS (Unaudited) *(In millions)*

	Three Months Ended September 30,
	2026						2025						% Change
	U.S.		ROW		Total		U.S.		ROW		Total		(Total Sales)
Dupixent^(a)	$	5,064.1	$	1,476.4	$	6,540.5	$	3,618.8	$	1,238.2	$	4,857.0	35%
EYLEA HD^(b)	$	698.8	$	384.0	$	1,082.8	$	430.6	$	232.4	$	663.0	63%
EYLEA^(b)	$	399.7	$	258.7	$	658.4	$	680.6	$	621.4	$	1,302.0	(49%	)
Total EYLEA HD and EYLEA	$	1,098.5	$	642.7	$	1,741.2	$	1,111.2	$	853.8	$	1,965.0	(11%	)
Libtayo^(c)	$	395.8	$	154.2	$	550.0	$	219.1	$	146.1	$	365.2	51%
Praluent^(d)	$	81.5	$	179.4	$	260.9	$	67.7	$	148.0	$	215.7	21%
Kevzara^(a)	$	192.7	$	62.9	$	255.6	$	102.9	$	51.1	$	154.0	66%
Lynozyfic	$	18.6	$	0.4	$	19.0	$	0.8	$	—	$	0.8	*
Other products^(e)	$	56.2	$	35.1	$	91.3	$	43.1	$	28.0	$	71.1	28%

	Nine Months Ended September 30,
	2026						2025						% Change
	U.S.		ROW		Total		U.S.		ROW		Total		(Total Sales)
Dupixent^(a)	$	13,183.6	$	4,235.2	$	17,418.8	$	9,453.2	$	3,414.0	$	12,867.2	35%
EYLEA HD^(b)	$	1,763.5	$	1,082.8	$	2,846.3	$	1,130.6	$	620.5	$	1,751.1	63%
EYLEA^(b)	$	1,285.0	$	955.1	$	2,240.1	$	2,170.9	$	2,068.8	$	4,239.7	(47%	)
Total EYLEA HD and EYLEA	$	3,048.5	$	2,037.9	$	5,086.4	$	3,301.5	$	2,689.3	$	5,990.8	(15%	)
Libtayo^(c)	$	1,024.5	$	453.1	$	1,477.6	$	659.4	$	367.4	$	1,026.8	44%
Praluent^(d)	$	222.8	$	549.4	$	772.2	$	190.3	$	440.7	$	631.0	22%
Kevzara^(a)	$	436.6	$	169.7	$	606.3	$	271.4	$	151.2	$	422.6	43%
Lynozyfic	$	45.5	$	1.2	$	46.7	$	0.8	$	—	$	0.8	*
Other products^(e)	$	187.3	$	95.0	$	282.3	$	116.3	$	81.5	$	197.8	43%

Note: The table above includes net product sales of Regeneron-discovered products. Such net product sales are recorded by the Company or others, as further described in the footnotes below.
* Percentage not meaningful or greater than 100%
^(a) Sanofi records global net product sales of Dupixent and Kevzara, and the Company records its share of profits in connection with global sales of such products within Collaboration revenue
^(b) The Company records net product sales of EYLEA HD and EYLEA in the United States, and Bayer records net product sales outside the United States. The Company records its share of profits in connection with sales outside the United States within Collaboration revenue.
^(c) The Company records global net product sales of Libtayo and pays Sanofi a royalty on such sales
^(d) The Company records net product sales of Praluent in the United States. Sanofi records net product sales of Praluent outside the United States and pays the Company a royalty on such sales, which is recorded within Other revenue.
^(e) Included in this line item are products which are sold by the Company and others. Refer to “Third Quarter 2026 Financial Results” section above for a listing of net product sales recorded by the Company. Not included in this line item are net product sales of ARCALYST^®, which are recorded by Kiniksa.

Posted in UncategorizedTagged GlobeNewswire

Sigenergy Launches SigenStor Neo in West Africa at Nigeria Energy 2026

Posted on October 30, 2026 by Ravi Shankar

World-first all-in-one energy storage system with Smart Port and Backup Port integration brings greater flexibility, resilience and intelligent energy management to West African homes

LAGOS, Nigeria, Oct. 30, 2026 (GLOBE NEWSWIRE) — Sigenergy (06656.HK) has announced the West African launch of SigenStor Neo, its next-generation all-in-one residential energy storage system, at Nigeria Energy 2026, currently underway at the Landmark Centre in Lagos.

The regional launch introduces Sigenergy’s latest residential energy innovation to West Africa, bringing together energy storage, power conversion, backup capability and intelligent energy management within one integrated platform.

For many Nigerian households, reliable home energy can depend on a combination of grid electricity and alternative energy sources. This creates a strong need for flexible systems capable of bringing solar generation, battery storage and backup power together within a more integrated home energy ecosystem.

At the centre of SigenStor Neo is its Smart Port and Backup Port architecture. As the world’s first all-in-one energy storage system to integrate both a dedicated Smart Port and Backup Port, SigenStor Neo is designed to become the intelligent core of the home energy ecosystem.

Sigenergy

“West Africa is an important market for Sigenergy, with customers looking for reliable and flexible ways to manage increasingly complex home energy needs. SigenStor Neo is designed to bring different energy resources together within one intelligent ecosystem, giving homeowners greater flexibility in how they generate, store and manage their energy. We are excited to introduce the next generation of SigenStor to West Africa at Nigeria Energy 2026,”
– Jade Martyn, Sales Director – Africa at Sigenergy

Bringing Multiple Energy Sources Together

One of SigenStor Neo’s most significant innovations is the flexibility provided by its Smart Port.

The Smart Port can connect compatible third-party inverters, external generators and EV chargers, enabling different energy resources and devices to operate as part of a more integrated home energy system.

This has important practical relevance for Nigerian households that may use generator backup alongside grid electricity and solar. Rather than operating entirely independently, an external generator can form part of the wider SigenStor Neo energy ecosystem.

For homeowners who already have solar equipment installed, the ability to connect compatible third-party inverters also provides greater flexibility when upgrading or expanding an existing energy system.

As household energy requirements evolve, the same architecture creates a pathway to incorporate additional devices and energy resources without requiring the entire system to be redesigned around separate, isolated components.

Reliable Backup When It Matters

Alongside its connectivity features, SigenStor Neo has been engineered to provide dependable household backup power.

The system delivers 0 ms load-side disruption and up to 200% peak power output capacity, helping household loads continue operating when grid power is interrupted.

Its dedicated Backup Port provides flexible extended power supply to household loads during unexpected grid outages, while the Smart Port enables additional backup resources such as an external generator to be incorporated where required.

Together, these capabilities provide homeowners with greater flexibility in how grid electricity, stored energy and additional backup sources are configured and managed.

For households where continuity of power is a priority, this integrated approach allows SigenStor Neo to function as more than a battery system. It becomes the central platform through which multiple energy resources can work together.

Storage That Can Grow with the Household

SigenStor Neo has also been designed around modularity and long-term flexibility.

Its architecture supports up to six vertically stacked battery modules, allowing homeowners to configure storage capacity around their current requirements while retaining the ability to expand the system as their energy needs grow.

This allows customers to start with a system suited to their present electricity consumption rather than necessarily designing an installation around their maximum future storage requirement from day one.

A built-in pack optimiser further supports future expansion by allowing compatible old and new batteries to operate within the same system.

The system also incorporates an eight-layer protection architecture, providing comprehensive protection throughout operation.

For households whose requirements may increase over time through additional appliances, increased solar capacity or future EV ownership, this modular design provides a practical pathway for expansion.

A Streamlined All-in-One Design

SigenStor Neo integrates the inverter, battery, power conversion system (PCS), energy management system (EMS) and gateway into a single streamlined platform.

For installers, this reduces the number of separate components required within a residential energy system and simplifies the overall installation architecture.

Lightweight modules with lifting handles, a single side cover for wiring and an optimised terminal layout and installation process are designed to further reduce deployment time and on-site labour.

The result is a more compact and integrated system for homeowners, while providing installers with a simplified approach to system deployment.

Sigenergy

AI-Powered Home Energy Management

SigenStor Neo forms part of Sigenergy’s wider “AI in All” strategy, which integrates artificial intelligence throughout the company’s energy ecosystem.

At the heart of this intelligent management layer is SigenAgent, the energy industry’s first all-domain AI agent, operating through mySigen App 4.0.

Rather than requiring homeowners to manually manage every operating parameter, SigenAgent enables users to define broader objectives, such as reducing electricity costs or maintaining sufficient backup power.

The system can then analyse operating conditions and coordinate connected hardware in support of those objectives.

For a home managing multiple energy sources, this combination of intelligent software and integrated hardware can simplify energy management while providing homeowners with greater visibility and control over how electricity is generated, stored and used.

Introducing SigenStor Neo to West Africa

The launch of SigenStor Neo at Nigeria Energy 2026 marks the system’s introduction to the West African market and another step in Sigenergy’s continued expansion across the region, including key markets such as Nigeria, Ghana, Côte d’Ivoire, Sierra Leone, Liberia and Togo.

Nigeria provides a strong platform for the regional launch, with growing interest in distributed solar, energy storage and flexible residential energy solutions capable of responding to different household requirements.

By bringing together solar, storage, grid electricity, backup resources and AI-driven energy management within one integrated ecosystem, SigenStor Neo introduces a new level of flexibility for homeowners seeking greater control over their energy.

Sigenergy is showcasing SigenStor Neo throughout Nigeria Energy 2026, taking place from 27-29 October at the Landmark Centre in Lagos.

About Sigenergy

Founded in 2022 and headquartered in Shanghai, Sigenergy (06656.HK) is a technology-driven company focused on innovation in the new energy sector. Leveraging advanced digital intelligence and a highly skilled talent base, the company has expanded into photovoltaic (PV) generation, smart energy storage and high-efficiency electric vehicle (EV) charging.

Guided by its “AI in All” strategy, Sigenergy integrates artificial intelligence across its product ecosystem to deliver safer, smarter and more efficient energy solutions for households worldwide.

MEDIA ENQUIRIES

Charl Ducray
charl@sigenergy.com
www.sigenergy.com

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/37d3f7ae-5499-41cb-bbb0-ae155341355e
https://www.globenewswire.com/NewsRoom/AttachmentNg/611fc03b-f5aa-40a2-926f-9c2660d6af46

Posted in UncategorizedTagged GlobeNewswire